Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
IN.PACT Admiral continues to demonstrate long-term clinical outcomes, even in patients considered to be at high risk of restenosis and repeat interventions.
The IN.PACT Admiral DCB features a proprietary FreePac™ coating solution that allows for the release of drug into the tissue through the restenotic window.
Meet Robert Canterbury, who was diagnosed with peripheral artery disease (PAD), and see how IN.PACT Admiral DCB helped get him back on his feet.
More information (see more) Less information (see less)
Third-party brands are trademarks of their respective owners.
Primary patency not assessed after three years.
Publications on file with Medtronic.
Data comes from different individual studies and may differ in a head-to-head comparison, and therefore may not be predictive of clinical results.
Laird JA, Schneider PA, Jaff MR, et al. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. 5-year results from the IN.PACT SFA Trial. Circ Cardiovasc Interv. June 2019;12(6):e007702.
Tepe G. 5-year results from the IN.PACT Global Study Prespecified Cohorts: ISR, CTO and Long Lesions. Presented at VIVA, 2021.
FDA. PMA P140010: Summary of safety and effectiveness data. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p140010. Accessed May 10, 2022.
FDA. PMA P190019: FDA Summary of safety and effectiveness data. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P190019. Accessed May 10, 2022.
Virmani R. Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model. Catheter Cardiovasc Interv. January 1, 2014;83(1):132-140.
FDA. PMA P160049: FDA summary of safety and effectiveness data. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160049. Accessed May 10, 2022.